Rokit Healthcare로킷헬스케어

Rokit Healthcare's revenue has grown fast, but it is still loss-making, heavily indebted, and its share price has fallen sharply over the past year.

Rokit Healthcare sells AI-driven regenerative medicine equipment and single-use kits, bioinks and software. In the trailing twelve months to H1 2026 it reported revenue of about ₩32.8B but an operating loss of about ₩15.1B and negative free cash flow of about ₩26.2B. The share price closed at ₩18,020 on 2026-10-22, down 53.4% over one year and well below its 52-week high of ₩153,800.

What stands out

• Revenue rose 100.2% in 2025 to about ₩26.2B, after a 5.6% rise in 2024, but the company has not yet turned this into profit: 2025 net income was a loss of about ₩2.8B and the trailing twelve-month operating margin is -46.1%.
• Liabilities are about 15 times equity (1,509.9%), with borrowings of about ₩25.0B against cash of about ₩20.2B.
• The 2023 net income figure of ₩16.6B is positive despite an operating loss of ₩7.4B; the filings given do not explain this, so it should be checked in the original report.
• Valuation metrics are stretched: price-to-book is 46.6 and price-to-sales is 9.6, while P/E is not meaningful because earnings are negative. The company pays no dividend.
• Recent filings include an amended annual report, an amended half-year report, a convertible share conversion price adjustment and several insider shareholding reports. Foreign ownership rose from 1.8% to 6.2% over about 60 days, while retail investors were net buyers over the last 20 days.

What to watch

• The company says it is pursuing termination of a US distributor contract and that this is unrelated to product defects; the outcome and any effect on overseas revenue are not in the data.
• The convertible share conversion price adjustment and the recent conversion exercise could add shares and dilute existing holders; the data does not show how many shares are involved.
• The next periodic results and whether operating losses narrow, since the data shows no forecasts or analyst targets.